Objective: To compare the efficacy of the CAMS-2005 and CAMS-2009 regimens in treating children with non-core binding factor acute myeloid leukemia (non-CBF AML) and to study the prognosis factors.
Methods: A total of 161 children who were initially diagnosed with non-CBF AML from April 2005 to December 2015 were enrolled as study subjects, and were divided into a CAMS-2005 regimen group (n=52) and a CAMS-2009 regimen group (n=109) according to the chemotherapy regimen provided. The efficacy was retrospectively compared between the two groups.
Results: The complete remission (CR) rate at the first course of treatment was higher in the CAMS-2009 regimen group than that in the CMAS-2005 regimen group (63.3% vs 46.2%; P<0.05). There were no significant differences between the two groups in treatment-related mortality rate (11.9% vs 17.3%), recurrence rate (27.5% vs 28.8%), and three-year overall survival (OS) rate (44%±5% vs 28%±6%) (P>0.05). Children who achieved CR at the first course of treatment had significantly higher OS and event-free survival rates than those who did not achieved CR (P<0.01).
Conclusions: The CAMS-2009 regimen is superior to the CAMS-2005 regimen in improving the CR rate in children with non-CBF AML after induction treatment. Whether CR is achieved at the first course of treatment can affect the OS rate of children with non-CBF AML.
目的: 回顾性分析比较非核心结合因子（CBF）急性髓系白血病（AML）儿童采用CAMS-2005方案及CAMS-2009方案治疗的疗效及预后的影响因素。
方法: 选择2005年4月至2015年12月161例初诊为非CBF-AML患儿为研究对象，根据化疗方案分为CAMS-2005方案组（n=52）和CAMS-2009方案组（n=109），对两种化疗方案疗效进行回顾性分析。
结果: CAMS-2009方案组第1个疗程完全缓解率高于CAMS-2005方案组（63.3% vs 46.2%，P < 0.05）。CAMS-2009方案组治疗相关病死率（11.9% vs 17.3%）、复发率（27.5% vs 28.8%）、3年总生存（OS）率（44%±5% vs 28%±6%）与CAMS-2005方案组相比差异无统计学意义（P > 0.05）。第1个疗程获得完全缓解患儿的3年OS率、3年无事件生存率高于第1个疗程未完全缓解患儿（P < 0.01）。
结论: CAMS-2009方案较CAMS-2005方案可改善非CBF-AML患儿诱导治疗完全缓解率，第1个疗程是否获完全缓解可影响非CBF-AML患儿OS率。